Fig. 3
From: Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist
Involvement of IL17A Signaling in Disease Progression. a Plasma IL17A level during 7-day IMQ modelling (n = 4), from day 2 to day 7, plasma were collected 24 h after IMQ application on the previous day. b Plasma IL17A concentration of each group on day 5, 0.5 h after IMQ application (n = 6). c Expression level for mRNA of IL17A targeted genes in mice skin collected on day 5 after IMQ treatment (n = 6). d Staining intensity (n = 6) and e representative image of immunohistochemistry result for IL6 infiltration in mice skin on day 5. Data was expressed as mean ± SEM *P < 0.05, **P < 0.01 comparing to model group